The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Highlights in Waldenström’s macroglobulinemia at ASH 2022
In this video, Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the Waldenström’s macroglobulinemia (WM) abstracts he is looking forward to at the 2022 ASH Annual Meeting, including data on the non-covalent Bruton’s tyrosine kinase (BTK) inhibitor pirtobrutinib, disease profiling based on multiomic studies, and results from the combination of ibrutinib and venetoclax. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
